IGFBP2 and glioblastoma: Plasma IGFBP-2 level significantly discriminated the survival of the two GBM subgroups, with a mean OS of 303.6±24.9 days (median OS, 313 days; 95% CI, 244.0–382.0 days) for patients with plasma IGFBP-2>627.5 ng/ml versus a mean OS of 589.3±29.8 days (median OS, 568 days; 95% CI, 536.2–599.8 days, Fig 3A) for patients with plasma IGFBP-2<627.5 ng/ml.